Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06346626
Other study ID # 2WIN-S2024
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date April 1, 2024
Est. completion date June 1, 2024

Study information

Verified date March 2024
Source He Eye Hospital
Contact Guanghao Qin
Phone 18842664420
Email qinguanghao2020@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Myopia, also known as short-sightedness or near-sightedness, is a prevalent condition that typically emerges during childhood and early adulthood. It occurs when the eye elongates excessively, causing images of distant objects to focus in front of the retina, leading to blurred distance vision. The number of people with myopia is increasing every year, reaching half of the world's population by 2050. The global potential productivity loss due to uncorrected refractive errors was $244 billion in 2015. Due to the strong association between high myopia and pathological changes in the choroid, retina, and sclera, leading to irreversible vision loss, and the fact that correcting the refractive error does not halt the progression of pathology, the prevention of myopia, especially high myopia, has emerged as a crucial international public health concern. In ocular examinations of children under noncycloplegic conditions, the influence of accommodation cannot be disregarded. Cycloplegic refraction is widely regarded as the gold standard in epidemiological assessment of refractive errors in pediatric populations. Moreover, due to children's decreased cooperation and unreliable responses, subjective refraction tests are less valued, and objective tests under cycloplegia are preferred. The portable vision screener 2WIN-S is a binocular tool that detects various ocular abnormalities and measures the refraction of both eyes. Along with measuring phorias/tropias in prismatic diopters and objective refraction in the range of -15D to +15D, 2WIN-S also captures additional features. This study employed the cycloplegic condition to measurements using 2WIN-S, ARK-1 and subjective testing, we wanted to test the reliability and accuracy of 2WIN-S.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 150
Est. completion date June 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 3 Years to 18 Years
Eligibility Inclusion Criteria: - The subject who can not cooperate to complete the inspection; - Have other eye diseases that cannot be dilated (such as angle-closure glaucoma, shallow front, etc.; - Have other conditions that affect eye refraction, such as strabismus and previous eye surgery; - Investigate other conditions that the doctor thinks should not be involved. Exclusion Criteria: - Age 3-18 years old; - The best corrected visual acuity is better than 0.1 (logmar); - Patients undergoing eye mydriasis examination in the outpatient department of our hospital; - Volunteer to participate in the study.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
He Eye Hospital

References & Publications (8)

Baird PN, Saw SM, Lanca C, Guggenheim JA, Smith Iii EL, Zhou X, Matsui KO, Wu PC, Sankaridurg P, Chia A, Rosman M, Lamoureux EL, Man R, He M. Myopia. Nat Rev Dis Primers. 2020 Dec 17;6(1):99. doi: 10.1038/s41572-020-00231-4. — View Citation

Hashemi H, Khabazkhoob M, Asharlous A, Soroush S, Yekta A, Dadbin N, Fotouhi A. Cycloplegic autorefraction versus subjective refraction: the Tehran Eye Study. Br J Ophthalmol. 2016 Aug;100(8):1122-7. doi: 10.1136/bjophthalmol-2015-307871. Epub 2015 Nov 5. — View Citation

Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016 May;123(5):1036-42. doi: 10.1016/j.ophtha.2016.01.006. Epub 2016 Feb 11. — View Citation

Magome K, Morishige N, Ueno A, Matsui TA, Uchio E. Prediction of cycloplegic refraction for noninvasive screening of children for refractive error. PLoS One. 2021 Mar 15;16(3):e0248494. doi: 10.1371/journal.pone.0248494. eCollection 2021. — View Citation

Morgan IG, Iribarren R, Fotouhi A, Grzybowski A. Cycloplegic refraction is the gold standard for epidemiological studies. Acta Ophthalmol. 2015 Sep;93(6):581-5. doi: 10.1111/aos.12642. Epub 2015 Jan 18. — View Citation

Naidoo KS, Fricke TR, Frick KD, Jong M, Naduvilath TJ, Resnikoff S, Sankaridurg P. Potential Lost Productivity Resulting from the Global Burden of Myopia: Systematic Review, Meta-analysis, and Modeling. Ophthalmology. 2019 Mar;126(3):338-346. doi: 10.1016/j.ophtha.2018.10.029. Epub 2018 Oct 17. — View Citation

Paff T, Oudesluys-Murphy AM, Wolterbeek R, Swart-van den Berg M, de Nie JM, Tijssen E, Schalij-Delfos NE. Screening for refractive errors in children: the plusoptiX S08 and the Retinomax K-plus2 performed by a lay screener compared to cycloplegic retinoscopy. J AAPOS. 2010 Dec;14(6):478-83. doi: 10.1016/j.jaapos.2010.09.015. — View Citation

Wilson LB, Melia M, Kraker RT, VanderVeen DK, Hutchinson AK, Pineles SL, Galvin JA, Lambert SR. Accuracy of Autorefraction in Children: A Report by the American Academy of Ophthalmology. Ophthalmology. 2020 Sep;127(9):1259-1267. doi: 10.1016/j.ophtha.2020.03.004. Epub 2020 Apr 18. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The optometric result (2WIN-S) The optometric result of 2WIN-S One day
Secondary The optometric result(ARK-1) The optometric result between 2WIN-S and ARK-1 One day
Secondary The optometric result(subjective refraction) The optometric result between 2WIN-S and subjective refraction One day
Secondary The optometric result The optometric result between 2WIN-S and ARK-1 One day
See also
  Status Clinical Trial Phase
Completed NCT03253393 - Smart Touch Non-dispensing Handling Studies N/A